Canaccord Genuity Maintains Buy on Evolent Health, Lowers Price Target to $9
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Richard Close maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $16 to $9.
Canaccord Genuity analyst Richard Close maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $16 to $9.